查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971068

催產素市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、通路、地區和競爭格局分類，2021-2031年

Oxytocin Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Antepartum, Postpartum), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球催產素市場預計將從 2025 年的 15.5 億美元成長到 2031 年的 23.1 億美元，複合年成長率為 6.91%。

催產素是一種強效的子宮收縮胜肽激素，主要用於透過促進子宮收縮來引產和控制產後出血。市場成長主要受妊娠併發症日益增多以及醫療機構廣泛實施積極的第三產程管理通訊協定的推動。此外，全球剖腹產數量的增加使得定期預防性使用該藥物以減少術中出血成為必要，從而導致已開發市場和新興市場對合成製劑和非專利的需求持續成長。市場持續發展面臨的一大障礙是藥品供應鏈的脆弱性。這導致無菌注射劑頻繁且嚴重短缺，造成採購瓶頸。這種不穩定性使得製造商無法有效地滿足全球需求並實現收入目標。據美國醫療保健系統藥劑師協會稱，2024年第一季醫療保健產業出現了創紀錄的323種藥品短缺，嚴重影響了催產素等基本急救藥物的供應。這些物流方面的限制，加上嚴格的低溫運輸儲存要求，仍然是市場持續擴張的主要障礙。

市場概覽
預測期 2027-2031
市場規模：2025年 15.5億美元
市場規模：2031年 23.1億美元
複合年成長率：2026-2031年 6.91%
成長最快的細分市場 產後
最大的市場 北美洲

市場促進因素

產後出血（PPH）發生率的上升是催產素市場的重要促進因素，常規使用促進子宮收縮的藥物已成為標準治療方法。由於產後出血仍然是全球孕產婦死亡的主要原因之一，醫療衛生系統正在積極實施主動管理通訊協定，要求在分娩第三產程預防性使用催產素。這種臨床需求正在推動催產素的大規模採購，尤其是在分娩風險較高的地區，預防過度出血是首要任務。根據聯合國人口基金2024年母嬰健康基金年度影響報告，到2025年7月，將有超過600萬名孕婦透過該基金的服務獲得安全分娩護理，這凸顯了保護孕產婦健康所需藥物的巨大規模。同時，耐熱性和新型製劑的進步正在從根本上擴大市場覆蓋範圍，克服了資源匱乏地區低溫運輸的障礙。這些創新確保了產品即使在電力供應不穩定的熱帶氣候下也能有效發揮作用，開闢了新的通路，並減少了廢棄物。費林製藥在2024年永續發展報告中指出，2024年將向中低收入國家供應150萬劑耐熱Carbetocin縮宮素，較去年同期成長50%。此外，現有學名藥生產商也在提高產能以滿足不斷成長的需求。希克瑪製藥的全球注射劑業務在2024年實現了9%的收入成長，達到13億美元。這反映了包括催產素在內的基本無菌藥物的強勁需求。

市場挑戰

無菌注射劑藥品供應鏈的脆弱性是全球催產素市場成長的主要障礙。這種脆弱性源於無菌肽激素，其中對無菌性和穩定性的嚴格品管至關重要。全球數量有限的生產設施一旦出現生產線故障或監管合規問題，就會即時造成供應瓶頸。這種中斷阻礙了製造商利用日益成長的子宮收縮藥物臨床需求，直接導致商機的損失和已開發地區及新興市場擴張的停滯。因此，醫療保健機構經常面臨這種關鍵急性治療藥物供應不穩定的問題，導致市場停滯。美國系統藥劑師協會 (ASHP) 報告稱，2024 年將出現 95 種新的藥品短缺，其中約 50% 與注射劑相關。供應中斷的頻繁發生，尤其是在注射劑領域，凸顯了催產素市場面臨的嚴峻物流風險。除非確保可靠的庫存水平，否則將無法持續滿足剖腹產率上升和產後出血處理通訊協定實施後帶來的不斷成長的需求，從而有效地限制市場價值的潛在上限。

市場趨勢

隨著臨床研究拓展至神經精神疾病和行為障礙領域，這種荷爾蒙的效用正超越其傳統的產科應用。藥廠正積極研發鼻腔製劑，以應對普拉德-威利症候群和泛自閉症障礙等複雜疾病。這一趨勢代表著一項策略性舉措，旨在利用該激素調節與飽腹感和社交聯繫相關的神經通路的能力。據Tonix Pharmaceuticals公司稱，其用於治療普拉德-兒童症候群（一種影響美國不到20萬人的遺傳性疾病）的強化催產素療法TNX-2900於2024年3月獲得美國食品藥品監督管理局（FDA）授予的罕見兒童疾病適應症資格。同時，隨著醫療保健系統尋求更安全的鴉片類藥物危機解決方案，催產素作為非鴉片類鎮痛替代療法的研究正在加速推進。研究機構正在評估催產素的止痛特性，尤其著眼於降低老化社會和慢性疼痛患者的鴉片類藥物成癮。這項臨床研究旨在檢驗催產素作為輔助性治療能否降低鴉片類藥物的劑量需求並減輕藥物依賴風險。據佛羅裡達大學稱，研究人員於2024年9月獲得美國國立衛生研究院（NIH）414,375美元的津貼，用於開展一項臨床試驗，評估合成催產素在減少老年人鴉片類藥物使用方面的有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球催產素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（產前、產後）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美催產素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲催產素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區催產素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲催產素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲催產素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球催產素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bimeda Group
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Grindeks
  • Pfizer, Inc.
  • Weefsel Pharma
  • EVER Pharma
  • AdvaCare Pharma
  • Fresenius Kabi AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23826

The Global Oxytocin Market is projected to expand from USD 1.55 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a CAGR of 6.91%. As a potent uterotonic peptide hormone, oxytocin is primarily administered to induce labor and manage postpartum hemorrhage by stimulating uterine contractions. The market is largely driven by the increasing prevalence of pregnancy-related complications and the universal implementation of Active Management of the Third Stage of Labor protocols across medical institutions. Additionally, the rising number of cesarean section deliveries worldwide necessitates the routine prophylactic use of this medication to minimize surgical blood loss, ensuring sustained demand for both synthetic and generic formulations in developed and emerging economies. A significant obstacle to market continuity is the fragility of the pharmaceutical supply chain, which frequently leads to critical inventory shortages of sterile injectables. This instability results in procurement bottlenecks that hinder manufacturers from efficiently meeting global requirements and achieving revenue targets. According to the American Society of Health-System Pharmacists, the healthcare sector faced a record 323 active drug shortages in the first quarter of 2024, a crisis that severely impacts the availability of essential acute care medications like oxytocin. These logistical constraints, exacerbated by strict cold-chain storage requirements, remain a primary barrier to consistent market expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.55 Billion
Market Size 2031USD 2.31 Billion
CAGR 2026-20316.91%
Fastest Growing SegmentPostpartum
Largest MarketNorth America

Market Driver

The rising incidence of Postpartum Hemorrhage (PPH) serves as a critical driver for the oxytocin market, necessitating the routine administration of uterotonics as a standard of care. Since PPH remains the leading cause of maternal mortality globally, healthcare systems are aggressively adopting active management protocols that mandate prophylactic oxytocin use during the third stage of labor. This clinical necessity fuels high-volume procurement, particularly in regions with elevated obstetric risks where preventing excessive blood loss is paramount. The United Nations Population Fund's 'Maternal and Newborn Health Fund Annual Impact Report 2024' noted that more than 6 million pregnant women accessed safer delivery care through their services in July 2025, highlighting the immense scale of medication required to safeguard maternal health. Simultaneously, advancements in heat-stable and novel formulations are fundamentally expanding market reach by overcoming cold-chain logistical barriers in low-resource settings. These innovations ensure product efficacy in tropical climates with unreliable electricity access, thereby opening new distribution channels and reducing wastage. Ferring Pharmaceuticals reported in its 'Sustainability Report 2024' that it supplied 1.5 million doses of heat-stable Carbetocin Ferring to lower-middle-income countries in 2024, a 50% increase from the previous year. Furthermore, established generic manufacturers are strengthening production capabilities to meet this growing need; Hikma Pharmaceuticals' global Injectables business achieved a 9% revenue increase to $1.3 billion in 2024, reflecting resilient demand for essential sterile medications including oxytocin.

Market Challenge

The fragility of the pharmaceutical supply chain for sterile injectables acts as a primary impediment to the growth of the global oxytocin market. This vulnerability stems from the complexity of manufacturing sterile peptide hormones, where strict quality control regarding sterility and stability is non-negotiable. When manufacturing lines fail or regulatory compliance issues arise at the limited number of global production facilities, immediate procurement bottlenecks occur. These disruptions prevent manufacturers from capitalizing on the rising clinical demand for uterotonics, directly causing lost revenue opportunities and stalling market expansion in both developed and emerging regions. Consequently, healthcare providers often face inconsistent availability of this critical acute care medication, forcing market stagnation. The American Society of Health-System Pharmacists identified 95 new drug shortages in 2024, with nearly 50% involving injectable medications. This high prevalence of supply failures specifically within the injectable category underscores the severe logistical risks facing the oxytocin market. Without reliable inventory levels, the market cannot sustain the volume growth required by the increasing rates of cesarean sections and postpartum hemorrhage protocols, effectively capping potential valuation.

Market Trends

The Expansion of Clinical Research into Neuropsychiatric and Behavioral Disorders is extending the hormone's utility beyond traditional obstetrics. Pharmaceutical developers are aggressively investigating intranasal formulations to address complex conditions like Prader-Willi syndrome and autism spectrum disorder. This trend highlights a strategic move to capitalize on the hormone's ability to modulate neural pathways associated with satiety and social bonding. According to Tonix Pharmaceuticals, in March 2024, the company received Rare Pediatric Disease Designation from the FDA for TNX-2900, a potentiated oxytocin therapy for Prader-Willi syndrome, a genetic disorder affecting fewer than 200,000 people in the United States. Concurrently, the Investigation of Oxytocin as a Non-Opioid Alternative for Pain Management is accelerating as healthcare systems seek safer solutions to the opioid crisis. Research institutions are evaluating the analgesic properties of oxytocin specifically to reduce opioid dependence in aging populations and patients with chronic pain. This clinical focus aims to validate oxytocin as an adjunctive therapy that can lower required opioid dosages and mitigate addiction risks. According to the University of Florida, researchers secured a $414,375 grant from the National Institutes of Health in September 2024 to conduct a clinical trial assessing synthetic oxytocin's efficacy in curbing opioid use among older adults.

Key Market Players

  • Bimeda Group
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Grindeks
  • Pfizer, Inc.
  • Weefsel Pharma
  • EVER Pharma
  • AdvaCare Pharma
  • Fresenius Kabi AG

Report Scope

In this report, the Global Oxytocin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oxytocin Market, By Indication

  • Antepartum
  • Postpartum

Oxytocin Market, By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Oxytocin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oxytocin Market.

Available Customizations:

Global Oxytocin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oxytocin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Antepartum, Postpartum)
    • 5.2.2. By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Oxytocin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channels
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oxytocin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channels
    • 6.3.2. Canada Oxytocin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channels
    • 6.3.3. Mexico Oxytocin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channels

7. Europe Oxytocin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channels
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oxytocin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channels
    • 7.3.2. France Oxytocin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channels
    • 7.3.3. United Kingdom Oxytocin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channels
    • 7.3.4. Italy Oxytocin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channels
    • 7.3.5. Spain Oxytocin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channels

8. Asia Pacific Oxytocin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channels
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oxytocin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channels
    • 8.3.2. India Oxytocin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channels
    • 8.3.3. Japan Oxytocin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channels
    • 8.3.4. South Korea Oxytocin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channels
    • 8.3.5. Australia Oxytocin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channels

9. Middle East & Africa Oxytocin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channels
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oxytocin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channels
    • 9.3.2. UAE Oxytocin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channels
    • 9.3.3. South Africa Oxytocin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channels

10. South America Oxytocin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channels
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oxytocin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channels
    • 10.3.2. Colombia Oxytocin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channels
    • 10.3.3. Argentina Oxytocin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channels

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oxytocin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bimeda Group
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline PLC
  • 15.3. Merck & Co., Inc.
  • 15.4. Grindeks
  • 15.5. Pfizer, Inc.
  • 15.6. Weefsel Pharma
  • 15.7. EVER Pharma
  • 15.8. AdvaCare Pharma
  • 15.9. Fresenius Kabi AG

16. Strategic Recommendations

17. About Us & Disclaimer